TYROBP (TYRO Binding Protein), also known as DAP12 (DNAX-activating protein 12), is a critical adaptor protein that mediates signaling in microglia and other immune cells. TYROBP forms a signaling complex with TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), and both genes are strongly associated with Alzheimer's disease (AD) risk 1. This pathway page explores the molecular mechanisms by which TYROBP/DAP12 influences microglial function, neuroinflammation, and neurodegeneration in AD.
The TREM2-TYROBP signaling axis represents one of the most significant breakthroughs in understanding AD pathogenesis since the identification of APOE risk variants. Genome-wide association studies (GWAS) have consistently identified both TREM2 and TYROBP as major genetic determinants of AD risk, with effect sizes comparable to the APOE ε4 allele 1. This genetic evidence, combined with extensive mechanistic studies, has established microglial signaling through TYROBP as a central pathway in AD pathophysiology.
¶ Gene and Protein Structure
The TYROBP gene (OMIM: 604304) encodes a type I transmembrane adaptor protein consisting of three distinct domains 2:
- Extracellular N-terminal domain: A short extracellular region that facilitates protein-protein interactions
- Transmembrane domain: Contains a charged aspartic acid residue critical for interaction with TREM2
- Intracellular ITAM motif: Immunoreceptor Tyrosine-based Activation Motif that transduces activation signals
The TYROBP protein is 113 amino acids in length and has a molecular weight of approximately 12 kDa. The ITAM motif contains two tyrosine residues (Y65 and Y76) that become phosphorylated upon receptor engagement, creating docking sites for downstream signaling proteins 3.
TYROBP is expressed primarily in cells of the myeloid lineage 2:
- Microglia (highest expression in brain)
- Macrophages
- Monocytes
- Dendritic cells
- Osteoclasts
- Some subsets of NK cells
- Mast cells
In the brain, TYROBP is almost exclusively expressed in microglia, where it partners exclusively with TREM2 2. Single-cell RNA sequencing studies have confirmed that TYROBP expression is one of the defining markers of disease-associated microglia (DAM) or neurodegenerative microglia (NG) 4.
¶ Ligand Recognition and Receptor Engagement
The TREM2-TYROBP signaling cascade is initiated by ligand binding to TREM2. Multiple ligands have been identified that engage this receptor complex 5:
- Amyloid-beta (Aβ) plaques: Aβ oligomers and fibrils can directly bind to TREM2
- APOE: APOE lipoproteins, particularly APOE4 isoform, serve as major TREM2 ligands 6
- Lipids: Various lipid species including phosphatidylserine, cardiolipin
- Dead cells: Apoptotic cell remnants expose phosphatidylserine
- TREM2 ligands from neurons: Neuronal debris and stressed cells release TREM2 ligands
flowchart TD
subgraph Ligands ["TREM2 Ligands"]
L1 [Aβ plaques]
L2 [APO ["E lipoproteins"]
L3 [Phosphatidylserine]
L4 [Lipids]
L5 [Dead cell debris]
end
subgraph Receptor ["Receptor Complex"]
R["TREM2 receptor"]
R2 [TYROB ["P/DAP12"]
end
subgraph Signaling ["Downstream Signaling"]
S1 [ITA ["M phosphorylation"]
S2 [SY ["K recruitment"]
S3 [SR ["C family kinases"]
S4 [PI3 ["K/AKT"]
S5 [ER ["K/MAPK"]
S6 [NF-κB]
S7 [Calcineurin/NF ["AT"]
S8 [mTOR pathway]
end
subgraph Outcomes ["Cellular Outcomes"]
O1 [Phagocytosis]
O2 [Cell survival]
O3 [Inflammatory response]
O4 [Metabolic fitness]
O5 [Cytoskeletal reorganization]
O6 [Gene transcription]
end
L1 --> R
L2 --> R
L3 --> R
L4 --> R
L5 --> R
R --> R2
R2 --> S1
S1 --> S2
S2 --> S3
S3 --> S4
S3 --> S5
S3 --> S6
S3 --> S7
S3 --> S8
S4 --> O1
S4 --> O2
S4 --> O4
S5 --> O3
S5 --> O6
S6 --> O3
S6 --> O6
S7 --> O6
S8 --> O2
S8 --> O4
The PI3K/AKT pathway is a central mediator of TREM2-TYROBP signaling 7:
- PI3K activation: SYK phosphorylates and activates PI3K
- PIP3 generation: PI3K converts PIP2 to PIP3
- AKT recruitment: AKT is recruited to the membrane
- AKT activation: PDK1 and mTORC2 phosphorylate AKT
Downstream effects:
- Cell survival through BAD phosphorylation
- Metabolic reprogramming (increased glycolysis)
- Protein synthesis via mTORC1
- Cytoskeletal organization
- Translation of pro-inflammatory cytokines
The ERK/MAPK cascade regulates gene expression and cellular differentiation 8:
- RAF activation: SOS recruits and activates RAF
- MEK activation: RAF phosphorylates MEK1/2
- ERK activation: MEK phosphorylates ERK1/2
- Nuclear translocation: ERK enters the nucleus
Downstream effects:
- CREB-mediated gene transcription
- Cell proliferation and differentiation
- Cytokine production
- Phagocytic activity modulation
NF-κB activation drives inflammatory gene transcription 9:
- IKK activation: SYK activates IKK complex
- IκB degradation: NF-κB is released from IκB
- Nuclear translocation: p65/p50 translocates to nucleus
Downstream effects:
- TNF-α, IL-1β, IL-6 production
- Chemokine secretion (CCL2, CCL3, CCL5)
- Inflammatory amplification
- Acute phase response
¶ Calcium Signaling and Calcineurin/NFAT Pathway
Calcium influx through TYROBP-activated channels activates calcineurin 10:
- Calcium influx: Store-operated calcium entry
- Calcineurin activation: Calcium-bound calmodulin activates calcineurin
- NFAT dephosphorylation: Calcineurin dephosphorylates NFAT
- Nuclear translocation: NFAT enters nucleus
Downstream effects:
- Cytokine gene transcription
- Cell differentiation programs
- Immune response modulation
¶ TREM2 Variants and TYROBP Signaling
Multiple TREM2 coding variants significantly increase AD risk 11:
| Variant |
Amino Acid Change |
Risk Ratio (OR) |
Effect on Signaling |
| R47H |
Arginine → Histidine |
~2.5-4× |
Severe impairment |
| R62H |
Arginine → Histidine |
~2-3× |
Moderate impairment |
| R251G |
Arginine → Glycine |
~2× |
Moderate impairment |
| H157Y |
Histidine → Tyrosine |
~2× |
Partial impairment |
| T96K |
Threonine → Lysine |
~3× |
Severe impairment |
TREM2 variants impair signaling through multiple mechanisms 12:
- Reduced ligand binding: Some variants decrease affinity for Aβ and APOE
- Impaired receptor clustering: Variants affect receptor dimerization
- Reduced TREM2 expression: Some variants cause mRNA instability
- Altered trafficking: Variants affect receptor maturation and surface expression
A 2025 study demonstrated that monoallelic TYROBP deletion is a novel risk factor for AD, confirming the critical role of this adaptor protein 13.
TYROBP signaling is essential for efficient microglial phagocytosis 14:
flowchart TD
A["TREM2-TYROBP Signaling"] --> B["SYK Activation"]
B --> C["PI3K Activation"]
C --> D["Actin Polymerization"]
D --> E["Phagocytic Cup Formation"]
E --> F["Target Recognition"]
F --> G1 [Aβ Particles]
F --> G2 [Apoptotic Cells]
F --> G3 [Synaptic Debris]
F --> G4 [Tau Aggregates]
G1 --> H["Phagosome Formation"]
G2 --> H
G3 --> H
G4 --> H
H --> I["Phagosome Maturation"]
I --> J["Lysosomal Fusion"]
J --> K["Degradation"]
K --> L["Antigen Presentation"]
M["TYROBP Variants"] --> N["Impaired SYK Activation"]
N --> O["Reduced Phagocytic Capacity"]
O --> P["Aβ Accumulation"]
O --> Q["Synaptic Loss"]
- Aβ clearance: TYROBP signaling is essential for microglial phagocytosis of amyloid plaques 15
- Cell debris removal: Critical for clearing dead neurons and synaptic fragments
- Immune surveillance: Maintains baseline microglial activity
- Tau clearance: Emerging evidence for TYROBP in tau aggregate clearance
TYROBP signaling has complex, context-dependent effects on inflammation 16:
Pro-inflammatory effects:
- NF-κB activation → TNF-α, IL-1β, IL-6 production
- MAPK activation → AP-1 mediated cytokine transcription
- Inflammasome activation → IL-1β processing and release
Anti-inflammatory effects:
- IL-10 production induction
- TGF-β secretion
- TREM2-mediated suppression of excessive inflammation
Homeostatic functions:
- Baseline microglial surveillance
- Metabolic fitness maintenance
- Lipid metabolism regulation
The balance depends on ligand context, cellular environment, and disease stage.
- TYROBP is significantly associated with AD risk (GWAS p < 5×10⁻⁸) 1
- Expression quantitative trait loci (eQTLs) in brain tissue affect AD risk 17
- The AD risk allele leads to reduced TYROBP expression
- TREM2 and TYROBP are co-expressed in microglia 2
- TREM2 risk variants impair signaling through TYROBP 11
- This explains the similar phenotypic effects of TREM2 and TYROBP variants
Recent research has shown that MS4A4A and MS6A genes, also AD risk genes, negatively regulate TREM2 and microglia states, providing additional evidence for the importance of this signaling axis 18.
¶ TYROBP and Tau Pathology
TYROBP signaling influences tau pathology through multiple mechanisms 19:
- Direct phagocytosis: Microglia can phagocytose tau aggregates
- Secretion of kinases: Microglia secrete tau-phosphorylating kinases
- Inflammation: Chronic inflammation promotes tau pathology
- Impairment effects: Reduced TYROBP signaling leads to tau accumulation
TREM2 agonists represent the most advanced therapeutic approach 20:
| Agent |
Company |
Stage |
Mechanism |
| AL002 |
Alector/GSK |
Phase 2 |
Agonistic antibody |
| NPT122 |
Neurimmune |
Phase 1 |
Agonistic antibody |
| AF-1059 |
AbbVie |
Preclinical |
Small molecule |
SYK inhibitors can modulate downstream signaling 21:
- Partial inhibition may reduce excessive inflammation
- Must preserve beneficial phagocytic signaling
- Challenges with blood-brain barrier penetration
- Increase TYROBP expression in microglia
- Deliver functional TYROBP protein
- Viral vector-mediated gene delivery
Emerging strategies combine TREM2 activation with:
- Anti-Aβ antibodies (lecanemab, donanemab)
- Anti-tau therapies
- Neuroprotective agents
A 2026 study demonstrated differential downstream signaling in microglia lacking TREM2 or TYROBP, providing important mechanistic insights for therapeutic development 22.
The disease-associated microglia (DAM) program represents a transcriptional response to neurodegeneration 4. TYROBP is one of the core genes defining the DAM signature:
Stage 1 DAM (early):
- Upregulation of TYROBP, TREM2
- Increased phagocytic genes
- Metabolic reprogramming
Stage 2 DAM (late):
- Further TYROBP induction
- Lysosomal genes upregulated
- Neurotoxicity genes expressed
TYROBP signaling critically regulates microglial metabolism 7:
Metabolic Effects:
- Increased glycolysis (Warburg effect)
- Enhanced mitochondrial function
- Improved ATP production
- Lipid metabolism modulation
Implications for AD:
- Metabolic dysfunction in AD microglia
- Reduced TYROBP signaling → impaired metabolism
- Energy deficits contribute to neurodegeneration
¶ TYROBP and the Complement System
¶ Cross-talk with C1q and C3
TYROBP signaling interacts with the complement system in multiple ways 23:
- Synaptic pruning: Complement proteins tag synapses for removal
- TYROBP regulation: TREM2-TYROBP mediates microglial pruning
- Impaired pruning: Risk variants disrupt normal pruning
- C1q can modulate TREM2-TYROBP signaling
- Synaptic loss in AD involves both pathways
- Therapeutic targeting may need to address both
TYROBP signaling affects blood-brain barrier (BBB) function 24:
- Pericyte function regulation
- Endothelial cell signaling
- Leukocyte trafficking control
- BBB dysfunction in AD
- BBB permeability affects drug delivery
- TYROBP modulators must cross BBB
- Targeted delivery strategies needed
TYROBP is deeply involved in lipid metabolism 6:
- APOE interaction: Major link between lipid metabolism and immunity
- Cholesterol efflux: Regulated by TREM2-TYROBP
- Lipid droplet formation: Affected in AD microglia
- APOE4 reduces TREM2-TYROBP signaling 6
- Lipid binding differences between APOE isoforms
- Therapeutic implications for APOE4 carriers
¶ TYROBP in Aging and Senescence
- TYROBP expression decreases with age 25
- Impaired signaling in aged microglia
- Cellular senescence effects
- TYROBP in senescence-associated secretory phenotype (SASP)
- Senolytic approaches may benefit AD
- Intersection of aging and neurodegeneration
- CSF sTREM2: Soluble TREM2 fragment reflects microglial activation 26
- CSF TYROBP: Direct measurement of pathway activity
- Cytokines: IL-1β, TNF-α, IL-6 as downstream markers
- PET microglia imaging: TSPO PET reflects microglial activation
- Structural MRI: Correlations with microglial burden
- Biomarker development for patient selection
- Treatment response monitoring
- Disease progression tracking
- BBB penetration: Most large molecules don't cross BBB
- Target engagement: Difficult to measure in brain
- Dosing: Optimal dosing unclear for many approaches
- Biomarkers: Need better surrogate endpoints
- Dose-response: U-shaped curve possible (too much vs. too little)
- Timing: May need intervention at specific disease stages
- ApoE4 interaction: Different effects in APOE4 carriers
- Sex differences: Potential gender-specific effects
- Clinical trials: Long timelines and high costs
- Patient selection: Need biomarkers for enrichment
- Combination therapy: Regulatory complexity
- Competitive landscape: Multiple programs in development
- Single-cell profiling: Understanding microglial heterogeneity
- Spatial transcriptomics: Location-specific TYROBP effects
- iPSC models: Patient-derived microglia for testing
- Organoid systems: Brain organoid-microglia interactions
- Genotype-based: Tailored to TREM2/TYROBP genotype
- Stage-based: Different interventions at different disease stages
- Combination therapy: Multi-target approaches
- Personalized medicine: Individualized treatment plans
The TREM2-TYROBP signaling axis represents a fundamental pathway in AD pathophysiology. TYROBP serves as the critical adaptor protein translating TREM2 activation into downstream cellular responses that regulate microglial phagocytosis, inflammation, metabolism, and survival. The strong genetic evidence linking both TREM2 and TYROBP to AD risk underscores the importance of this pathway in disease pathogenesis.
Understanding the detailed molecular mechanisms of TYROBP signaling provides opportunities for therapeutic intervention. Multiple approaches including TREM2 agonists, SYK modulators, and gene therapy are under development. However, significant challenges remain in achieving effective brain penetration, establishing appropriate biomarkers, and determining optimal treatment timing.
As research continues, the TREM2-TYROBP pathway will likely become an important component of precision medicine approaches for AD, potentially in combination with other therapeutic targets.
The TYROBP/DAP12 microglia signaling pathway stands as one of the most important molecular mechanisms in Alzheimer's disease pathogenesis. Through its essential role as the adaptor protein for TREM2, TYROBP mediates critical microglial functions including phagocytosis of amyloid plaques, clearance of toxic protein aggregates, regulation of neuroinflammation, and maintenance of cellular metabolic fitness. The strong genetic evidence linking both TREM2 and TYROBP variants to AD risk, with effect sizes approaching that of the APOE ε4 allele, underscores the central importance of this signaling axis in disease development and progression.
Understanding TYROBP's role in microglial biology has opened new therapeutic avenues for AD treatment. The development of TREM2 agonists and other modulators of this pathway represents one of the most promising approaches in current AD drug development. However, the complexity of TYROBP signaling, with its context-dependent pro-inflammatory and anti-inflammatory effects, requires careful therapeutic targeting to avoid unintended consequences. Future research focusing on biomarker development, optimal treatment timing, and combination therapies will be essential to fully realize the therapeutic potential of targeting the TYROBP pathway in Alzheimer's disease.
As our understanding of microglial heterogeneity and the role of neuroinflammation in neurodegenerative diseases continues to grow, TYROBP will remain a central focus of research efforts aimed at developing disease-modifying treatments for AD and related disorders.
- Complement and microglia in AD (2020)
- Microglia and BBB (2020)
- Aging microglia (2020)
- CSF sTREM2 as biomarker (2019)
- TREM2 Microglia Pathway in Alzheimer's Disease
- APOE Gene
- Neuroinflammation in Alzheimer's Disease
- Microglia in Alzheimer's Disease
- Disease-Associated Microglia (DAM)